Clinical Validation of the cobas 4800 HPV Test for Cervical Screening Purposes

ABSTRACT This study shows that the clinical performance and reproducibility of the cobas 4800 HPV test for high-risk human papillomavirus (HPV) detection fulfill the criteria as formulated in international guidelines of HPV test requirements for cervical screening purposes. Accordingly, the cobas 4800 HPV test can be considered clinically validated for cervical screening.

[1]  J. Berkhof,et al.  Evaluation of 14 triage strategies for HPV DNA‐positive women in population‐based cervical screening , 2012, International journal of cancer.

[2]  Mario Rodríguez-Domínguez,et al.  Evaluación de un sistema de PCR a tiempo real (cobas 4800) para la detección separada de los genotipos 16 y 18 y otros genotipos de alto riesgo del virus del papiloma humano en la prevención del cáncer cervical , 2011 .

[3]  T. Wright,et al.  High-risk human papillomavirus testing in women with ASC-US cytology: results from the ATHENA HPV study. , 2011, American journal of clinical pathology.

[4]  G. Demmler-Harrison,et al.  Congenital cytomegalovirus: Public health action towards awareness, prevention, and treatment. , 2009, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[5]  C. Meijer,et al.  Validation of high-risk HPV tests for primary cervical screening. , 2009, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[6]  J. Berkhof,et al.  Comparison of HPV and cytology triage algorithms for women with borderline or mild dyskaryosis in population‐based cervical screening (VUSA‐screen study) , 2009, International journal of cancer.

[7]  Francisco A. R. Garcia,et al.  Evaluation of a Prototype Real-Time PCR Assay for Carcinogenic Human Papillomavirus (HPV) Detection and Simultaneous HPV Genotype 16 (HPV16) and HPV18 Genotyping , 2009, Journal of Clinical Microbiology.

[8]  J. Cuzick,et al.  Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older , 2009, International journal of cancer.

[9]  P. Snijders,et al.  GP5+/6+ PCR followed by Reverse Line Blot Analysis Enables Rapid and High-Throughput Identification of Human Papillomavirus Genotypes , 2002, Journal of Clinical Microbiology.

[10]  M. Mateos,et al.  [Evaluation of a prototype real-time PCR assay for the separate detection of human papilloma virus genotypes 16 and 18 and other high risk human papillomavirus in cervical cancer screening]. , 2011, Enfermedades infecciosas y microbiologia clinica.